MediciNova, Inc.
Stock Price Chart
2026/08/13 UpdatedPrice Trend
2026/08/13 UpdatedPrice & Trading Details
2026/08/13 UpdatedPRICE
TRADING
Analyst Recommendations 4 analysts
Updated 2026/08/01Earnings Calendar
Updated 2026/08/01Recent Earnings
| Date | EPS Est. | EPS Actual | Surprise |
|---|---|---|---|
| 2026/05/14 | ¥-10.37 | ¥-7.91 | +23.8% |
| 2026/02/20 | ¥-14.53 | ¥-7.75 | +46.7% |
| 2025/11/12 | ¥-18.50 | ¥-9.29 | +49.8% |
| 2025/08/14 | ¥-17.56 | ¥-10.34 | +41.1% |
Shareholder Composition
Updated 2026/08/01Top Mutual Funds / ETFs
Updated 2026/08/01Major Holders
Updated 2026/08/01| Fund Name | Ownership | Shares | Change |
|---|---|---|---|
|
VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund
|
611.0K | +28.71% | |
|
Fidelity Concord Street Trust-Fidelity Extended Market Index Fund
|
251.7K | -1.36% | |
|
iShares Trust-iShares Micro-Cap ETF
|
159.0K | +28.13% | |
|
Fidelity Concord Street Trust-Fidelity Total Market Index Fund
|
87.6K | 0.00% | |
|
SCHWAB CAPITAL TRUST-Schwab Total Stock Market Index Fund
|
71.5K | 0.00% | |
|
Fidelity Concord Street Trust-Fidelity Series Total Market Index Fund
|
68.4K | 0.00% |
| Institution | Ownership | Shares | Change |
|---|---|---|---|
|
Essex Woodlands Management Inc.
|
1.1M | 0.00% | |
|
Blackrock Inc.
|
706.0K | +0.14% | |
|
Citigroup Inc.
|
635.7K | 0.00% | |
|
Vanguard Capital Management LLC
|
611.0K | +1.00% | |
|
Geode Capital Management, LLC
|
543.8K | +2.69% | |
|
Vanguard Fiduciary Trust Co
|
280.6K | +1.00% |
Financial Performance
2026/08/09 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2023 | 2025 | |
|---|---|---|
| Income Statement | ||
| Revenue | ¥1M | ¥0M |
| Gross Profit | - | ¥0M |
| Operating Income | -¥10M | -¥13M |
| Pretax Income | -¥10M | -¥13M |
| Net Income | -¥9M | -¥12M |
| EPS | -¥0.17 | -¥0.24 |
| Operating Margin | -990.03% | -3,242.47% |
| Balance Sheet | ||
| Total Assets | ¥66M | ¥46M |
| Total Equity | ¥62M | ¥42M |
| Total Liabilities | ¥4M | ¥4M |
| Cash | ¥51M | ¥31M |
| Interest-bearing Debt | ¥0M | ¥0M |
| Equity Ratio | 94.13% | 91.19% |
| D/E Ratio | 0.00 | 0.00 |
| Cash Flow | ||
| Operating CF | -¥7M | -¥10M |
| Investing CF | ¥40M | -¥0M |
| Financing CF | - | ¥0M |
| Free CF | -¥7M | -¥10M |
| Efficiency | ||
| ROE | -13.74% | -28.85% |
| ROA | -12.93% | -26.31% |
Latest IR Information
-
Fiscal Year Ending December 2026 Q2 Interim Financial Results Report [U.S. GAAP] (Consolidated)
The consolidated results for the second quarter of the fiscal year ending December 2026 show continued losses. Revenue is 645,423 thousand USD (interim), operating loss is △5,376,995 thousand USD, net loss attributable to parent company shareholders for the interim is...
Read more -
【MediciNova】Notice of Extension of Filing Deadline for Semiannual Report ｜ July 2026
MediciNova has applied to the Kanto Local Finance Bureau for an extension of the filing deadline for the fiscal year ending December 2026 semiannual report and reported that there have been no dissolutions or changes. It also includes details on...
Read more -
Notice Regarding Resolutions Passed at the Annual General Meeting of Shareholders
Read more -
Notification of Resolutions Passed at the Annual General Meeting of Shareholders
Read more -
Notice of Partial Amendment to Articles of Incorporation
Read more
Latest News (5 items)
-
Average Analyst Rating: strong_buy
Average Target Price: ¥-
Rating Score: 1.33 (Based on 4 analysts)
※1=Strong Buy, 5=Strong Sell
MediciNova Inc reports results for the quarter ended June 30 - Earnings Summary - TradingView ↗
Company Information
About
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, and glioblastoma, as well as prevention of acute respiratory distress syndrome. The company is also developing MN-001 (tipelukast), an orally bioavailable small molecule compound in Phase 2 clinical trial to treat fibrotic and other metabolic disorders, including nonalcoholic fatty liver disease and hypertriglycedemia. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.
